Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
stocks
Our view of ANZ’s strategic plan
stocks
Perplexing buyback from overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,299.00 | 21.90 | 0.24% |
CAC 40 | 8,077.00 | 157.38 | 1.99% |
DAX 40 | 24,181.37 | 55.57 | -0.23% |
Dow JONES (US) | 46,156.38 | 114.08 | -0.25% |
FTSE 100 | 9,424.75 | 28.02 | -0.30% |
HKSE | 25,910.60 | 469.25 | 1.84% |
NASDAQ | 22,528.38 | 6.68 | 0.03% |
Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
S&P 500 | 6,636.03 | 8.28 | -0.12% |
S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
SSE Composite Index | 3,912.21 | 46.98 | 1.22% |